Future of Biotransformation Science in the Pharmaceutical Industry.
Saved in:
| Title: | Future of Biotransformation Science in the Pharmaceutical Industry. |
|---|---|
| Authors: | Kramlinger VM; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Dalvie D; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Heck CJS; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Kalgutkar AS; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., O'Neill J; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Su D; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Teitelbaum AM; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Totah RA; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.). |
| Source: | Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2022 Mar; Vol. 50 (3), pp. 258-267. Date of Electronic Publication: 2021 Dec 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
